Prescription of anorectic and benzodiazepine drugs through notification B prescriptions in Natal, Rio Grande do Norte, Brazil by Nappo, Solange Aparecida et al.
*Correspondence: E. A. Carlini. Centro Brasileiro de Informações sobre Dro-
gas Psicotrópicas - CEBRID, Departamento de Psicobiologia, Universidade 
Federal de São Paulo - UNIFESP. Rua Botucatu, 862 - São Paulo. E-mail: 
carlini@psicobio.epm.br
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 46, n. 2, abr./jun., 2010
Prescription of anorectic and benzodiazepine drugs through 
notification B prescriptions in Natal, Rio Grande do Norte, Brazil
Solange Aparecida Nappo1, Elisaldo Araújo Carlini1,*, Maria Dalva Araújo2, 
Lúcio Flávio Sousa Moreira2
1Brazilian Information Center on Psychotropic Drugs, CEBRID, Department of Psychobiology, Federal University of São 
Paulo, 2Community Center, Brazilian Information Center on Psychotropic Drugs, CEBRID, Department of Social Sciences, 
Federal University of Rio Grande do Norte
A study was conducted on 22,158 special B prescriptions (notificações B) containing amphetamine-type 
anorectic drugs or benzodiazepines, obtained from compounding pharmacies or drugstores located in 
the city of Natal, RN, Brazil. The data obtained were compared with those from other Brazilian cities. 
Results showed that compounding pharmacies dispensed 85.4% of the prescriptions, indicating that 
these pharmacies filled out nearly 10 times more of these prescriptions than did the drugstores. The 
majority (83.5%) of B prescriptions issued for the compounding pharmacies were for women, where the 
female/male patient ratio ranged from 7.1/1.0 for mazindol to 10.3/1.0 for amfepramone. Similar results 
were obtained for the benzodiazepines with ratios of 1.9/1.0 for clonazepam to 15.6/1.0 for oxazepam. 
Omissions and mistakes were present in the B prescriptions, including missing information about the 
patient (in 49.6% of the documents) or about the pharmacies or drugstores (50.4%). There were cases 
where the name and/or CRM of the physician was lacking. It was noted that one medical doctor made 
out 1855 B prescriptions within one year. The same patient’s name appeared on 138 prescriptions, and 
the same RG (identification card number) was present in 125 others. Comparison of Natal’s data with 
those of several other Brazilian cities disclosed a striking similarity throughout Brazil, from Pelotas – 
Rio Grande do Sul State to Belem–Para State, revealing a practically identical medical/pharmaceutical 
behavior. This pattern of prescription/dispensation of amphetamine-type substances mostly to women 
for weight loss is therefore for cosmetic reasons. Consequently, there is an urgent need for an ethical 
review of this behavior.
Uniterms: Anorectic/prescription. Benzodiazepine/prescription. Obesity/treatment. Medicines/ rational 
use. Compounded medicine. Compounding pharmacy.
Foram examinadas 22.158 notificações B contendo substâncias anoréticas tipo-anfetamina ou de 
benzodiazepínicos, obtidas de drogarias e de farmácias de manipulação. Os dados foram comparados com 
os de outras cidades do Brasil, obtendo-se uma visão nacional sobre o assunto. Os achados mostraram que 
as farmácias de manipulação, dispensaram 85,4% das notificações, ou seja, as farmácias de manipulação 
atenderam cerca de 10 vezes mais do que as drogarias. A maioria (83,5%) das notificações B nas farmácias 
de manipulação eram destinadas às mulheres sendo a relação entre pacientes femininos/masculinos de 
7,1/1,0 no caso do mazindol e de 10,3/1,0 para a anfepramona. Dados semelhantes foram obtidos para 
os benzodiazepínicos: relação de 1,9/1,0 para o clonazepam até 15,6/1,0 para o oxazepam. Falhas e 
erros gritantes foram também observados no preenchimento das notificações B: ausência de dados de 
pacientes (em 49,6% dos documentos), do fornecedor (50,4%) etc. Houve casos de notificações sem o 
nome ou CRM do médico e um único médico prescreveu 1.855 notificações B; o nome de uma mesma 
compradora apareceu em 138 notificações e um mesmo RG em 125 outras. A comparação destes achados 
com os de outras cidades mostrou uma surpreendente semelhança, ao longo do país, desde Pelotas-RS 
até Belém-PA; evidenciando um padrão de comportamento médico/farmacêutico praticamente idêntico. 
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Este padrão de prescrição para mulheres destina-se mais para uma finalidade cosmética (perda de peso) 
do que para uma real necessidade terapêutica. É necessária uma revisão ética sobre este problema, que 
também tem sido observado e igualmente criticado em vários países.
Unitermos: Anoréticos/prescrição. Benzodiazepínicos/prescrição. Obesidade. Medicamentos/uso 
racional. Fórmulas magistrais. Farmácia de manipulação.
INTRODUCTION
Much is known in Brazil about the increased use of 
amphetamine-type anorectic drugs (e.g., amfepramone, 
fenproporex and mazindol) combined with anxiolytic 
benzodiazepines, for the purpose of anorexia and conse-
quent weight loss (Nappo, 1992, 1996); Nappo, Carlini, 
1994; Nappo, Oliveira, Morosini, 1998; Noto et al., 2002; 
Santos et al., 2007). This use is made possible by a physi-
cian, through “Notifição B” prescriptions, as exacted by 
Ordinance 344/98 of ANVISA (Brazil’s National Health 
Surveillance Agency); these prescriptions are stored in 
drugstores and compounding pharmacies for a minimum 
period of 2 years, allowing control of these dependence-
inducing substances.
Besides the B prescriptions (retained by authorities), 
physicians may also prescribe several medicines for their 
patients in the form of a compounded formulation which 
is filled out in a compounding pharmacy (Nappo, 1996; 
Nappo, Oliveira, Morosini, 1998).
The purpose of a compounded medication is to pro-
vide a customized prescription, specific for each patient, 
with a dosage and combination of drugs that do not exist 
in manufactured medicines from the pharmaceutical in-
dustry and are not commercially available: This commonly 
occurs when compounded medications are intended for 
weight loss, where the compounded product can contain 
one or more anorectics, benzodiazepines, diuretics, laxa-
tives, thyroid hormones, KCl, or gonadotrophin etc.
It should be noted that benzodiazepines and anorec-
tic amphetamines are also produced and sold as individual 
drugs under different commercial names (Nappo, Carlini, 
1994).
The use of anorectic amphetamines for aesthetic 
purposes (weight loss) has been strongly criticized in 
various countries in Latin America (Instituto de Salud 
Pública de Chile, 1992; Boletim CEBRID, 1993), United 
States (Rothblum, 1994), Spain (Butlleti Groc, 1993) and 
England (Thomas, Campbell, 1996), as well as by the 
International Narcotics Control Board (INCB, 2005), an 
agency linked to the United Nations.
However, despite questions over the therapeutic 
utility and the awareness of the toxic potential of these am-
phetamines (British National Formulary, 1994), the use of 
these drugs has risen unabated in many countries including 
Brazil. Thus, the INCB (2004) showed that in the 3-year 
periods of 1992 – 1994 and 2000 – 2002, the use of these 
drugs in Brazil was 7.40 and 6.78 DDDs (defined daily 
doses) per 1000 inhabitants, respectively, thus ranking the 
country second worldwide. Between 2002 and 2004, the 
use of these drugs in Brazil increased to 9.13 DDDs/1000 
inhabitants (INCB, 2005), making it the world leader in 
this unfortunate “competition”
Scientific studies by Brazilian authors have shown 
that the use of anorectic amphetamines has occurred in 
cities located in various different Brazilian states: Pelotas- 
Rio Grande do Sul State (Lima et al., 1998), São Paulo – 
São Paulo State (Azzolini, 2003), São Caetano do Sul and 
Diadema – São Paulo State (Noto et al., 2002), Ribeirão 
Preto – São Paulo State (Andrade, Andrade, Santos, 2004), 
Belo Horizonte – Minas Gerais State (Carneiro, Guerra Jr, 
Acursio, 2008), Goiania – Goias State (Cunha et al., 2002), 
Fortaleza – Ceara State (Romeu, Justino, Lima, 2008), São 
Luiz – Maranhão State (Mariz, Silva, Ferreira et al., 2002) 
and Belém – Para State (Borges et al., 2008).
The aim of present work, in collaboration with the 
Health Surveillance Agency (VISA) of the State Secre-
tariat for Health of Rio Grande do Norte State, Brazil, 
was to analyze the “Notificação B” prescriptions filled 
out by drugstores and compounding pharmacies in the 
city of Natal, and to extend the existing body of data on 
prescription of anorectic and anxiolytic drugs in Brazil by 
adding information on the State of Rio Grande do Norte.
MATERIAL AND METHODS
In 2002, 16 compounding pharmacies (establish-
ments that can supply and sell compounded formulations 
containing controlled drugs) and 24 drugstores (cannot 
supply; but can sell finished controlled products) were 
randomly chosen, such that the different regions of Natal 
were equally represented. In both types of establishments, 
the preparations containing amphetamines and/or benzo-
diazepines can only be sold after presentation and submis-
sion of B prescriptions. These prescriptions for 2002 were 
collected by technicians from VISA for analysis.
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A computer program was specially developed to 
obtain and analyze the following data contained in the B 
prescriptions. 
·	  name, stamp and CRM of physician;
·	  name and address of patient;
·	  name, address and telephone number of buyer;
·	  name of the medication, dose and number of units; 
·	  Information on the drugstore or pharmacy.
The following records based on all the data gathered 
were obtained:
·	 omissions in filling out the B prescriptions by the phy-
sician and by the prescription-filling establishment;
·	 number of prescriptions per type of prescription-
filling establishment;
·	 number of prescriptions by (and specialty of) phy-
sicians; 
·	 substances prescribed and time of use; 
·	 number of men and women to whom B prescriptions 
were issued.
RESULTS
Number of prescriptions per type of prescription-
filling establishment
A total of 25,949 B prescriptions containing ano-
rectic amphetamines or benzodiazepines were analyzed. 
These were collected from 16 compounding pharmacies 
and 24 drugstores. A total of 128 of the B prescriptions 
contained other types of substances and were not included.
As shown in Table I, 16 compounding pharmacies fil-
led out 22,158 B prescriptions containing benzodiazepines 
or amphetamines (85.4% of the total), whereas 24 drugsto-
res prepared only 3791 B prescriptions (14.6% of the total). 
In other words, each compounding pharmacy handled, on 
average, 1385 prescriptions for psychotropic medications 
in 2002, almost 10 times the number handled by the corres-
ponding drugstores in general (158 prescriptions prepared).
Gender of Patients
Table II shows that the vast majority (83.5%) of B 
notifications received by compounding pharmacies were 
prescribed for women where this was also the case for 
drugstores, albeit at a lower percentage (69.4%).
Errors/Omissions in filling out B prescriptions
Of the total of 26,077 B prescriptions issued (inclu-
ding 128 notifications that did not contain benzodiazepines 
or amphetamines), a large number were filled out with 
omissions.
TABLE I - Number of B prescriptions received by compounding pharmacies and drugstores in 2002, in Natal, RN, Brazil
Establishment Number of B prescriptions received Number of B prescriptions/
establishmenttype N N %
Compounding pharmacy 16 22,158 85.4% 1385 
Drugstore 24 3791 14.6% 158  
Total 40 25,949 100% ----------
* Only B prescriptions containing benzodiazepines or anorectic amphetamines were considered; 128 prescriptions containing 
other types of drugs were not considered.
TABLE II - Number of B prescriptions filled out for men and women in 2002 by compounding pharmacies (n=16) and drugstores 
(24). Natal - RN
Item Number of  B prescriptions
Compounding pharmacy Drugstore Total
N % N % N %
Total B prescriptions 22,158 100.0 3791 100.0 25,949* 100.0
   For women 18,505 83.5 2632 69.4 21,137 81.4
   For men 2907 13.1 935 24.6 3842 14.8
   Not identified 746 3.4 224 6.0 970 3.8
* Only B prescriptions containing benzodiazepines or anorectic amphetamines were considered; 128 prescriptions containing 
other types of drugs were not considered.
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These omissions occurred in practically all fields of 
the B prescription, particularly the address of the patients 
(12,244 = 46.95%), the stamp of the supplier (13,164 = 
50.48%) and information on the buyer (1921 = 7.4%), 
where in the last field there were omissions of patient 
name (336 prescriptions), address (665 prescriptions) and/
or number of identification document (594 prescriptions). 
Various aberrant facts were found: in 35 B prescriptions 
the name of the patient was missing; the same person, a 
female, appeared as the buyer in 138 prescriptions and 10 
other names appeared in 11 or more purchases. The same 
RG (ID) number appeared as the buyer in 125 prescrip-
tions, where 9 other RG numbers appeared in 20 or more 
prescriptions.
More seriously, 181 B prescriptions were found 
without the physician’s signature and/or stamp with the 
CRM number. Moreover, 10 physicians prescribed over 
570 B prescriptions, where the leading health care profes-
sional prescribed 1855 B prescriptions in 2002. Finally, 
one patient was issued 46 B prescriptions and nine other 
patients received 14 or more in 2002.
Substances prescribed
Besides overseeing the use of amphetamine-type 
drugs and benzodiazepines, the B prescription notification 
scheme also serves to control the use of some barbiturates 
and anti-parkinsonian medication trihexyphenidyl (com-
mercial product most utilized being Artane®), among 
others. The number of prescriptions of these drugs was 
much smaller: 20 for barbiturates and 23 for trihexyphe-
nidyl. However, a few B prescriptions were utilized for 
products that were not under the control of these special 
prescriptions, such as anabolic steroids (9 B prescriptions), 
antidepressants (20), antipsychotics (30), hypnotics (22) 
and anticonvulsants (4). In total, 128 B prescriptions were 
filled for these other substances.
Table III shows that women received the majority of 
prescriptions for anxiolytic medications: 10,143 out of a 
total of 13,420 or 75.6%, where only 19.3% of B prescrip-
tions were issued to male patients. Interestingly, 72.9% of 
the prescriptions for benzodiazepines were dispensed in 
16 compounding pharmacies, while the remaining 27.1% 
were filled out by 24 drugstores. These numbers contrast 
with the 128 B notifications for prescriptions for other 
medications, for which both types of establishments dis-
pensed practically the same numbers (48.1% and 51.9%, 
respectively). Table III shows that the most prescribed 
benzodiazepines in Natal, Rio Grande do Norte State in 
2002 were diazepam (7009 B prescriptions) and chlordia-
zepoxide (2495). Again, it should be noted that women 
were overwhelmingly the ones for whom all benzodiaze-
pines were prescribed, being from 2 times (clonazepam) 
to 16 times (oxazepam) more likely to receive these drugs 
than men.
Table IV shows that a total of 12,528 B prescriptions 
were for anorectic medications, where 87.8% were for 
women, i.e. 8.8 prescriptions for women for every pres-
cription for men. These numbers are very close to those 
for prescriptions for the three amphetamine-type drugs 
TABLE III - B prescriptions containing benzodiazepines, distributed by sex. Compounding pharmacies and drugstores were combined. 
Year, 2002. Natal – RN
Drug
                                                       Number of  B prescriptions
Sex Ratio
Total Female Male Not identified Female/
MaleN % N % N % N %
All benzodiazepines 13,420 100 10,146 75.6 2596 19.3 678 - 3.91
        Diazepam 7009 100 5572 79.5 1124 16.0 313 - 4.95
        Chlordiazepoxide 2495 100 1884 75.5 511 20.4 100 - 3.68
        Bromazepam 750 100 580 77.3 123 16.4 47 - 4.71
        Cloxazolam 748 100 541 72.3 154 20.6 53 - 3.51
        Clonazepam 714 100 433 60.6 221 30.9 60 - 1.95
        Lorazepam 493 100 343 69.5 119 24.1 31 - 2.88 
        Oxazepam 239 100 219 89.9 14 5.8 6 - 15.64
        Others* 972 100 - - - - - - -
*Camazepam, Flunitrazepam, Fludiazepam, Clorazepam, Estazolam, Flurazepam, Nitrazepam, Midazolam, Clobazam and 
Alprazolam.
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amfepramone, fenproporex and mazindol, when analyzed 
separately.
DISCUSSION
The present study showed that the supply and dis-
pensation of prescriptions containing amphetamine-type 
drugs, combined with benzodiazepines and other drugs or 
otherwise, is a very commonplace practice in Natal – Rio 
Grande do Norte State. This practice occurs predominan-
tly in compounding pharmacies which were responsible 
for 85% of the total supply. These drugs were practically 
always in the form of compounded formulations in combi-
nation with a large number of different substances. Thus, 
what occurs in various cities throughout Brazil in the states 
of Rio Grande do Sul, São Paulo, Goias, Maranhão, Minas 
Gerais, Ceará and Pará, i.e., the prescription and supply of 
medications for the purpose of weight loss, appears to be 
a medical-pharmaceutical practice of national proportion, 
covering all the major population regions of the country. 
Furthermore, in spite of the warnings issued by Brazilian 
and International Authorities this unreasonable prescrip-
tion/dispensation practice seems to continue unabated over 
time and geography. 
Thus, in Natal, as shown in the present study, wo-
men were the most frequent recipients of prescriptions of 
anorectics, receiving 87.8% of the total issued. In Belo 
Horizonte, 88% of the anorectics dispensed in 2003 were 
prescribed to women (Carneiro et al., 2008). A similar 
figure (86%) was detected for Belem in 2006 (Borges et 
al., 2008) and in Goiania (87%) between 2003 and 2004 
(Santos et al., 2007). In Fortaleza, women were also found 
to be the main users (74.5%) of anorectic medicaments in 
2005 (Romeu et al., 2008).
Also, coincident among the prescriptions of different 
cities, is the high number of irregularities, such as the lack 
of the address of the patient, identification (stamp) of the 
supplier, name of the buyer, signature and/or CRM of the 
physician, etc, revealing a generalized negligence in Brazil 
in the regulation of internationally controlled substances 
which are restricted due to their dependence-inducing 
capacity. Since 1988, the International Narcotics Control 
Board (INCB 1989) has repeatedly warned Brazil about 
the exaggerated use of anorectic amphetamines. In 2008, 
the UN-linked agency stressed: “131. Consumption of 
stimulants in Schedule IV continued to increase significan-
tly in some countries in the Americas, such as Argentina, 
Brazil and United States… 132. The Board reiterates its 
appeal to Governments… to monitor their trend of use…” 
(INCB, 2007).
Fortunately, the situation appears to have finally 
attracted attention: Brazil’s National Health Surveillance 
Agency (ANVISA, 2007) established the National System 
for the Management of Controlled Products (SNGPC) 
which imposes stricter control of the prescription and dis-
pensation of benzodiazepines and anorectic amphetami-
nes. Portugal, a country suffering from similar problems, 
has resolved the situation through an ordinance from the 
Ministry of Health, prohibiting the prescription and prepa-
ration of compounded formulations containing anorectic 
amphetamines (Portugal, Ministry of Health, 1999).
However, examination of the data of the present 
study and that of other studies on the use of anorectic drugs 
for the treatment of overweight reveals an ethical problem. 
Nappo et al. (2001) investigated the use of anorectics in 
more than 2000 patients from São Paulo and Brasilia, and 
in consonance with international studies, suggested that 
these drugs are used more for cosmetic reasons (due to a 
culture of being thin as a symbol of beauty) than for thera-
peutic reasons, thus not justifying their indiscriminate use.
Finally, various other authors have raised doubts 
over the ethics of the treatment of overweight with ano-
TABLE IV - B prescriptions containing amphetamine-type drugs, distributed by sex.  Compounding pharmacies and drugstores 
were combined in general.  Year, 2002. Natal – RN
Dru Number of B prescriptions
Sex Ratio
Total Female Male Not identified Female/
MaleN % N % N % N %
All 12,528 100 10,992 87.8 1244 9.9 292 2.3 8.8/1
Amfepramone 610 100 5413 88.7 523 8.2 164 3.1 10.3/1
Fenproporex 4475 100 3929 87.8 455 10.2 91 2.0 8.6/1
Mazindol 1952 100 1675 85.8 237 12.1 40 2.1 7.1/1
Phendimetrazine* 1 - - - - - - - -
*Drug not licensed in Brazil.
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rectic agents (Pace, Bolton, Reeves, 1991; Lustig, 1991; 
Begley, 1991; Wooley, Garner, 1991; Germov, Williams, 
Wright, 1995, 1996; Reidenberg, 2000). 
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